Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| Anti-GCC humanized antibody | Bispecific antibody | Oncology/Cancer | Solid Tumor | Preclinical | Global |
Expression analysis of human GUCY2C on HEK293/Human GUCY2C Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human GUCY2C Stable Cell Line or negative control cell using anti-human GUCY2C antibody followed by staining with PE anti-human IgG antibody.
5e5 of anti-GUCY2C CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human GUCY2C Protein, His Tag (Cat. No. GUC-HA2H4) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
Immobilized Monoclonal Anti-Human GUCY2C Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human GUCY2C, Fc Tag (Cat. No. GUC-HF255) with a linear range of 0.01-0.313 μg/mL (QC tested).
The purity of Mouse GUCY2C Protein, His Tag (Cat. No. GUC-M53H5) is more than 90% and the molecular weight of this protein is around 75-95 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Plecanatide | SP-304; GCRA | Approved | Synergy Pharmaceuticals Inc | Trulance | United States | Constipation; Chronic idiopathic constipation | Salix Pharmaceuticals | 2017-01-19 | Constipation; Irritable Bowel Syndrome; Chronic idiopathic constipation | Details |
| Plecanatide | SP-304; GCRA | Approved | Synergy Pharmaceuticals Inc | Trulance | United States | Constipation; Chronic idiopathic constipation | Salix Pharmaceuticals | 2017-01-19 | Constipation; Irritable Bowel Syndrome; Chronic idiopathic constipation | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| LCAR-G08 cells therapy(Legend Biotech) | LCAR-G08; (LCAR)-G08 | Phase 1 Clinical | Peking University | Gastrointestinal Neoplasms | Details |
| IM96 CAR-T cell Therapy | IM96 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Solid tumours; Pancreatic Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms | Details |
| GCC19CART | GCC19CART | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Rectal Neoplasms; Colorectal Neoplasms | Details |
| Gucy2c cart cell therapy (Innovative Cellular Therapeutics) | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Digestive System Neoplasms | Details | |
| LCAR-G08 cells therapy(Legend Biotech) | LCAR-G08; (LCAR)-G08 | Phase 1 Clinical | Peking University | Gastrointestinal Neoplasms | Details |
| IM96 CAR-T cell Therapy | IM96 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Solid tumours; Pancreatic Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms | Details |
| GCC19CART | GCC19CART | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Rectal Neoplasms; Colorectal Neoplasms | Details |
| Gucy2c cart cell therapy (Innovative Cellular Therapeutics) | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Digestive System Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
